Effects of Difenamizole on Content of Catecholamines and Metabolites in Mouse Brain

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Difenamizole on Content of Catecholamines and Metabolites in Mouse Brain EFFECTS OF DIFENAMIZOLE ON CONTENT OF CATECHOLAMINES AND METABOLITES IN MOUSE BRAIN Toshitaka NABESHIMA, Kazumasa YAMAGUCHI and Tsutomu KAMEYAMA Department of Chemical Pharmacology, Fuculty of Pharmaceutical Sciences, o University, Nagoya 468, Japan Meij Accepted April 13, 1978 In earlier studies in mice, a favorable correlation was found between the analgesic activity and cerebral concentration of 1,3-diphenyl-5-(2-dimethylaminopropionamide) pyrazole[difenamizole, DFZ] (1). In a subsequent study, Nabeshima and Kameyama reported that an analgesic effect was observed after intracerebral injection of DFZ in mice (2). DFZ markedly suppressed conditioned behavior maintained by a fixed ratio schedule of reinforcement, by differential reinforcement of a low rate schedule, and by the shuttle-box method (2, 3). Emotional behavior in rats with bilateral ablations of the olfactory bulb and aggressive behavior induced by isolation in male mice were suppressed by DFZ in anti nociceptive doses (4). These behavioral effects of DFZ were similar to the actions of low doses of chlorpromazine (CPZ) (2-4), in support of the view that DFZ acts via the central nervous system. It has been pointed out that central catecholaminergic and tryptaminergic mechanisms play a role in the analgesic action of morphine (5). We previously studied the effects of drugs which modify catecholaminergic or tryptaminergic mechanisms on the analgesic action of DFZ and morphine, and we suggested that the analgesic action of DFZ may be mediated by dopamine (DA), whereas that of morphine appears to be related to 5-hydroxy tryptamine and norepinephrine (NE) (6, 7). In the present investigation, the effects of analgesic doses of DFZ on cerebral catecholamines and their metabolites were investigated in mice. Male ddY mice, weighing 20-22 g, were used throughout the study. DFZ was given orally as a suspension in 5`/ gum arabic solution. Controls were given the vehicle only. DFZ concentrations were based on the closes producing an anti-nociceptive effect (6, 7). DFZ inhibited the acetic acid-induced writhing at low doses (25 and 50 mg/kg) (7) and the heat-induced reflexes were depressed with a high dose (150 mg/kg) (6). Since mice given DFZ, p.o., showed m axinmalanti-nociceptive activity 30--60 min after administration (6), the animals were decapitated 45 min after DFZ or vehicle administration. Brains were dissected within 1.5 min after decapitation according to the method of Glowinski and Iversen (8) and concentration of catecholannines and their metabolites in the brain was determined by the spectrolluorometrical procedure described by Karasavva cat al. (9, 10). Table 1 shows that there were significant differences in catecholamine levels in some regions between the DFZ.-treated and vehicle-treated animals. Striatal DA levels were sig nificantly higher in DFZ (25 and 50 mg/kg)-treated mice than in the controls. DFZ (25 150 mg/kg) produced a dose-dependent increase in dien--r mesencephalic NE in the treated mice. Cortical NE levels increased significantly after the DFZ-administration in a dose of 50 mg/kg. However, there were no significant variations in catecholamine levels in the cortex and the pons medulla oblongata relative to vehicle-treated mice. In Table I , it can be seen that DFZ in doses from 25 mg/ kg to 150 mg/kg produced a significant decrease in striatal 3-methoxytyramine (3-MT) in comparison to vehicle-treated mice. The dien f-mesencephalic normetanephrine (NM) levels were significantly lower in DFZ (25-150 mg/kg)-treated mice as compared to control mice. Significant changes in cortical 3-MT and NM, or pons-1 Medulla oblongatal NM concentrations were not observed. Striatal NM levels and dien mesencephalic and pons-' medulla oblongata) 3-MT levels were below determination limits. Since catechol-0-methyltransferase is known to be mainly located extraneuronally in , 644 (: the brain in contrast to monoamine oxidase (MAO) which is distributed both extra and intraneuronally, the concentrations of cerebral NM and 3-MT have been generally considered to reflect, under certain conditions, the amounts of NE and DA released from these mono aminergic neurons. Therefore, NM and 3-MT should be determined along with NE and DA in the same brain tissue when investigating the dynamics of these neurotransmitters in the brain (9). In our experiment, DFZ in analgesic doses decreased the concentrations of 3-MT in the striatum and NM in the dien -I-mesencephalon (Table 1) and these results suggest that DFZ may depress the release of catecholarnines from these monoaminergic neurons. In addition, we reported that the analgesic action of DFZ was antagonized by intracerebral injection of DA but not by NE (7). As the effect of DFZ was significantly potentiated by 6-hydroxydopamine, phenoxybenzamine and reserpine (7), the analgesic action of DFZ may be more related to the depression of dopaminergic than to the norepin ephrinergic system. Other workers reported that bilateral lesioning of the substantia nigra with a micro injection of 6-hydroxydopamine prolongs the reaction time of the tail flick in rats (11). Iwatsubo and Clouet reported that an increased rate of spontaneous firing of neurons in the substantia nigra was seen after the administration of morphine or haloperidol. The dopamine receptor agonists dopa and apomorphine decreased the firing rate in nigral neurons (12). Kuromi et a/. reported that a brief electrical stimulation of the substantia nigra induced a marked and long lasting inhibition of the somatosensory evoked potentials recorded from the centrum medianum of the thalamus and posterior hypothalamic area following sciatic stimulation in unanesthetized rabbits. All these results suggest that analgesia follows an increased rate of spontaneous firing in the substantia nigral neurons due to the decrease in dopaminergic neuronal activity. As stated above, an analgesic action of DFZ may be related to the dopaminergic system and DFZ may depress the release of DA in the striatum, therefore, DFZ may demonstrate an anlgesic action following depression of dopaminergic neuronal activity in the striatum. Anden et al. reported that CPZ produced a rise in the homovanillic acid (HVA, one of DA metabolites) content of the striatum (14). We gave CPZ (10 mg/kg, p.o.), and found that the concentration of HVA was significantly increased in the striatum (Table 2). CPZ reportedly enhances the accumulation of 3-MT and NM after MAO inhibition (15), however, TABLE 2. Effects of difenamizole and chlorpromazine on contents of dopamine, 3-methoxytyramine and homovanillic acid in mouse striatum in the experiments herein, DFZ decreased not only the concentration of 3-MT but also the concentration of HVA in the striatum. These results suggest that the mechanisms by which CPZ and DFZ depress catecholaminergic neurons differ. REFERENCES 1) KAMEYAMA,T., NIWA, H., KISARA, K. AND IWAIZUMI,H.: Studies on the absorption and distribution of 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole in rat. Yakugakn Zasshi 90, 829-834 (1970) (Abs. in English)2) NABESHIMA,T. AND KAMEYAMA,T.: Effects of dife namizole on behavior maintained by schedule of positive reinforcement. Folia pharmacol. japon. 73, 961-972 (1977) (Abs. in English)3) KAMEYAMA,T. AND NABESHIMA,T.: Effects of 1,3-3 diphenyl-5-(2-dimethylaminopropionamide)-pyrazole[difenamizole] on conditioned avoidance re sponse. Neuropharmacol. 17, 249-256 (1978)4) NABESHIMA,T., TAKAHASHI,K. AND KAMEL YAMA,T.: Effect of difenamizole on emotionality in experimental animals. Pharmacometrics 14, 497-502 (1977) (Abs. in English)5) TAKAGI, H.: Relationship between analgesic action of morphine and turnover of brain monoamines. Igaku no ayumi 79, 617-623 (1971) (in Japanese) 6) KAMEYAMA,T. ANDNABESHIMA, T.: Relationship between biogenic amines and analgesic action of difenamizole in heat induced reflexes. Folia pharmacol. japon. 72, 543-556 (1976) (Abs. in English)7) NABESHIMA,T., INA, M. AND KAMEYAMA,T.: Effects of monoamine-related drugs on inhibitory action of difenamizole to acetic acid-induced writhing in mice. Folia pharmacol. japon. 73, 907-917 (1977) (Abs. in English)8) GLOWINSKI,J. AND IVERSEN,L.L.: Regional studies of catecholamines in the rat brain-I, The disposition of [3H] norepinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J. Neurochem. 13, 655-669 (1966)9) KARASAWA, T., FURUKAWA,K., YOSHIDA,K. AND SHIMIZU, M.: A double column procedure for the simul taneous estimation of norepinephrine, normetanephrine, dopamine, 3-methoxytyramine and 5-hydroxytryptamine in brain tissue. Japan. J. Pharmacol. 25, 727-736 (1975)10) KARASAWA, T., NAKAMURA, I.AND SHIMIZU,M.: Simultaneous microdetermination of homovanillic acid and 5-hydroxyindoleacetic acid in brain tissue using Sephadex G-10 and QAE-Sephadex A-25. Life Sci. 15, 1465-1474 (1974)11) GROSSMANN,W., JURNA, I., NELL, T. AND THERES, C.: The dependence of the anti-nociceptive effect of morphine and other analgesic agents on spinal motor activity after central monoamine depletion. Europ. J. Pharmacol. 24, 67-77 (1973)12) IWATSUBO, K. AND CLOUET,D.H.: Effects of morphine and haloperidol on the electrical activity of rat nigro striatal neurons. J. Pharmacol. exp. Ther. 202, 429-436 (1977)13) KUROMI,H., SATOH,M. AND TAKAGI, H.: Inhibition of thalamic and hypothalamic somatosensory evoked potentials by stimu lation of substantia nigra and its modification by morphine and methotrimeprazine (levomeproma zine). Japan. J. Pharmacol. 26, 331-337 (1976)14) ANDEN, N.E., ROOS,B.E. AND WRERDINIUS, S.: Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci. 3, 149-158 (1964)15) CARLSSON,A. AND LINDQVIST,M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta pharmacol. toxicol. 20, 140-144 (1963).
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,361,492 B2 Tauber Et Al
    USOO8361492B2 (12) United States Patent (10) Patent No.: US 8,361,492 B2 Tauber et al. (45) Date of Patent: *Jan. 29, 2013 (54) DRUG DELIVERY SYSTEMAND METHODS (56) References Cited OF USE U.S. PATENT DOCUMENTS (75) Inventors: Shachar Tauber, Ozark, MO (US); 2003/0017208 A1* 1/2003 Ignatious et al. ............. 424/486 Randall Fuerst, Orangevale, CA (US); 2003/01931 18 A1 10/2003 Bango et al. 2003/0215624 A1 1 1/2003 Layman et al. Keela Davis, Springfield, MO (US); Lyle 2003/0232287 A1 12/2003 Bango Bowman, Pleasanton, CA (US); Gary 2004/0018226 A1 1/2004 Winek et al. Wnek, Cleveland, OH (US); Joseph J. 2005, OO67287 A1 3/2005 Fuerst et al. Bango, Jr., New Haven, CT (US) 2006/0085063 A1* 4/2006 Shastri et al. ................ 623, 141 2006/0171991 A1 8/2006 Bango 2006/0246113 A1 11/2006 Griffith et al. (73) Assignee: Ocugenics, LLC, Orangevale, CA (US) 2008.0002149 A1 1/2008 Fritsch et al. 2009/0217849 A1 9, 2009 Eastin et al. (*) Notice: Subject to any disclaimer, the term of this 2009, 0238858 A1 9, 2009 Kohnet al. patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 493 days. Office Action issued in related U.S. Appl. No. 12/416,802, dated Sep. This patent is Subject to a terminal dis 17, 2010, 11 pages. claimer. International Search Report and Written Opinion issued in PCT/ US2010/029126, dated Jan. 14, 2011, 11 pages. Kenawy, E.R. et al. “Controlled Release of Ketoprofen from (21) Appl. No.: 12/490,972 electrospun poly(vinyl alcohol) nanofibers' Materials Science & Engineering A 459, pp.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Synthesis and Pharmacological Activities of Pyrazole Derivatives: a Review
    Review Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review Khalid Karrouchi 1,2,3, Smaail Radi 2,*, Youssef Ramli 1, Jamal Taoufik 1, Yahia N. Mabkhot 4,*, Faiz A. Al-aizari 4 and M’hammed Ansar 1 1 Medicinal Chemistry Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco; [email protected] (K.K.); [email protected] (Y.R.); [email protected] (J.T.); [email protected] (M.A.) 2 LCAE, Department of Chemistry, Faculty of Sciences, University Mohamed I, 60000 Oujda, Morocco 3 Physicochemical service, Drugs Quality Control Laboratory, Division of Drugs and Pharmacy, Ministry of Health, 10100 Rabat, Morocco 4 Department of Chemistry, Faculty of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; [email protected] * Correspondence: [email protected] or [email protected] (S.R.); [email protected] (Y.N.M.); Tel.: +212-536-500-601 (S.R.) Received: 22 November 2017; Accepted: 5 January 2018; Published: 12 January 2018 Abstract: Pyrazole and its derivatives are considered a pharmacologically important active scaffold that possesses almost all types of pharmacological activities. The presence of this nucleus in pharmacological agents of diverse therapeutic categories such as celecoxib, a potent anti-inflammatory, the antipsychotic CDPPB, the anti-obesity drug rimonabant, difenamizole, an analgesic, betazole, a H2-receptor agonist and the antidepressant agent fezolamide have proved the pharmacological potential of the pyrazole moiety. Owing to this diversity in the biological field, this nucleus has attracted the attention of many researchers to study its skeleton chemically and biologically. This review highlights the different synthesis methods and the pharmacological properties of pyrazole derivatives.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • A Review on the Current Studies in Pyrazole Derivatives, Their Biological and Pharmacological Properties
    ejpmr, 2020,7(7), 867-887 SJIF Impact Factor 6.222 EUROPEAN JOURNAL OF PHARMACEUTICAL Review Article Pasha et al. European Journal of Pharmaceutical and Medical Research AND MEDICAL REEARCH ISSN 2394-3211 www.ejpmr.com EJPMR A REVIEW ON THE CURRENT STUDIES IN PYRAZOLE DERIVATIVES, THEIR BIOLOGICAL AND PHARMACOLOGICAL PROPERTIES Sadeq Hamood Saleh Azzam1 and M. A. Pasha2* 1Department of Studies in Chemistry, Janana Bharathi Campus, Bangalore University, Bangalore–560 056, India. 2Assistant Professor, Dept. of Chemistry, Sana’a University, Sana’a, Yemen. *Corresponding Author: M. A. Pasha Assistant Professor, Dept. of Chemistry, Sana’a University, Sana’a, Yemen. Article Received on 20/05/2020 Article Revised on 10/06/2020 Article Accepted on 30/06/2020 ABSTRACT The purpose of this present review is to highlight an overview of the versatile biological and pharmacological activities of pyrazole derivatives. The review deals with recent literature survey on the reported methods of synthesis and biological studies on pyrazole derivatives that are considered as most active heterocyclic compounds in nature; which possess a wide range of biological and various pharmacological activities such as: anti diabetic, hypnotic sedative, anti-inflammatory, antimicrobial, anticonvulsant, anthelmintic, antihypertensive, antiviral, anticancer, antioxidant, analgesic, antipyretic, antibacterial, anti-tuberculosis and so on. KEYWORDS: Pyrazole derivatives; biological activity; pharmacological activity; chemical synthesis. INTRODUCTION analyzed by comparing with the properties of benzene The term pyrazole was coined by Knorr in 1883. derivatives.[13] Pyrazole refers to a group of simple aromatic heterocyclic compounds which impart pharmacological Very similar to the other nitrogen containing effects on human beings. They are classified as alkaloids, heterocycles, different tautomeric structures can be although they are rare in nature.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,682,043 B2 Goldman (45) Date of Patent: Jun
    USOO9682043B2 (12) United States Patent (10) Patent No.: US 9,682,043 B2 Goldman (45) Date of Patent: Jun. 20, 2017 (54) METHOD OF PREPARATION OF MIXED FOREIGN PATENT DOCUMENTS PHASE CO-CRYSTALS WITH ACTIVE AGENTS JP 63-240936 A 10, 1988 JP 2003-522097 A 8, 1999 JP 20O2506876 A 3, 2002 (75) Inventor: David Goldman, Portland, CT (US) JP 2002356419 A 12/2002 WO WO99/47543 A2 9, 1999 (73) Assignee: MedCrystallForms, LLC, Hunt Valley, WO WO O2/O55,059 A2 T 2002 MD (US) WO WO O3/101392 A2 12/2003 WO WO 2004/043358 5, 2004 (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/078161 A1 9, 2004 patent is extended or adjusted under 35 WO WO 2004/082666 9, 2004 U.S.C. 154(b) by 537 days. OTHER PUBLICATIONS (21) Appl. No.: 11/008,034 Lide CRC Handbook of Chemistry and Physics 2003 p. 3-246 and 3-480. (22) Filed: Dec. 9, 2004 Meyerson et al. “Crystals, Crystal Growth, and Nucleation' Hand book of Industrial Crystallization Ed. Meyerson. Woburn: But (65) Prior Publication Data terworth-Heinemann 2002 p. 33, and 38-39.* US 2005/0181041 A1 Aug. 18, 2005 Payne et al. International Journal of Pharmaceutics 1999 177:231 245-k Zhang et al. Journal of Pharmaceutical Sciences 2007 96(5):990 Related U.S. Application Data 995.* (60) Provisional application No. 60/528.232, filed on Dec. Reutzel-Edens et al. Solid-state pharmaceutical development: 9, 2003, provisional application No. 60/559,862, filed Ensuring stability through salt and polymorph screening.
    [Show full text]